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latelet Function
ssessment to Predict Outcomes
fter Coronary Interventions
ype or Hope?*
ernando Alfonso, MD, PHD, FESC,†
ominick J. Angiolillo, MD, PHD, FACC‡
adrid, Spain; and Jacksonville, Florida
he primary aim of percutaneous coronary intervention
PCI) is to obtain excellent acute results in all attempted
esions without the shadow of any procedure-related com-
lication. Equally important is to guarantee that the benefits
f revascularization are maintained in the long run (1).
urrently, mainly as the result of improving technologies
nd adjunctive therapy, procedure-related complications
emain very low. Likewise, the advent of drug-eluting stents
as revolutionized the field, dissipating the fear of restenosis
1). Platelets are key players in ischemic complications in
atients undergoing PCI, and antiplatelet medication rep-
esents a cornerstone treatment. Novel and more potent
ntiplatelet regimens have been recently incorporated into
ur armamentarium to minimize procedural complications
nd the concerns of delayed thrombotic risks associated with
he profound antiproliferative effects of drug-eluting stents.
See page 1742
However, major issues with antiplatelet therapy remain
nresolved. These include: 1) the optimal therapeutic strat-
gy in patients undergoing PCI; 2) the optimal technique to
onitor its biologic effects in the clinical setting; and 3) the
ptimal length of dual antiplatelet treatment, especially in
atients receiving drug-eluting stents. This commentary
ill briefly focus on the first two problems.
LINICAL IMPLICATIONS
F STUDYING PLATELET FUNCTION
n this issue of the Journal, Hochholzer et al. (2) present the
esults of the EXCELSIOR (Impact of Extent of
lopidogrel-Induced Platelet Inhibition During Elective
tent Implantation on Clinical Event Rate) study. This
tudy elegantly demonstrates the clinical implications of
ssessing the extent of platelet aggregation in patients
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From †Interventional Cardiology, San Carlos University Hospital, Madrid, Spain;
nd the ‡Division of Cardiology, University of Florida—Shands Jacksonville, Jack-b
onville, Florida. Dr. Angiolillo is on the speakers’ bureau of and is a consultant for
anofi-Aventis and Bristol-Myers Squibb.ndergoing PCI. A large cohort of relatively low-risk
atients undergoing elective coronary stenting pre-treated at
east 2 hours before intervention with a 600-mg loading
ose of clopidogrel were evaluated. Patients showing higher
egrees of 5 mol/l adenosine diphosphate (ADP)-induced
latelet aggregation assessed by light transmission aggre-
ometry (LTA) immediately before intervention (those in
he 2 upper quartiles) suffered more 30-day major adverse
ardiac events (MACE). Notably, platelet aggregation
bove the absolute median value of the study population
14% of aggregation) carried a 6.7-fold risk of events.
urthermore, on multivariate logistic regression models
including all potential confounders such as baseline platelet
ggregation and time from clopidogrel loading to interven-
ion), platelet aggregation emerged as an independent pre-
ictor of early clinical outcome. These in-depth analyses are
f interest because the reported differences in demographic
haracteristics may have biased outcomes. This is the largest
rospective study supporting the prognostic implications of
latelet function measures performed before intervention in
atients pre-treated with a high clopidogrel loading dose
egimen. Importantly, the study also suggests the potential
linical utility of this tool to identify patients who may
enefit from more aggressive antithombotic approaches.
Hochholzer et al. (2) are to be commended for their
andmark study. This further piece of evidence on the
rognostic insights of platelet function assessment may
epresent a critical turning point in translational research
here the interest of measuring platelet activity will defi-
itely shift from bench to bedside. Hopefully, this will lead
o increased use of platelet function studies in daily clinical
ractice and set the basis for specific and individualized
herapeutic strategies. Nevertheless, owing to the potential
ajor clinical implications of the study as well as the
omplexity of platelet function analysis, some issues should
e addressed.
First, baseline platelet function accounted for a significant
mount of interindividual variability in platelet function and
p to 50% of residual platelet aggregation before interven-
ion depended on the variability in individual response to
lopidogrel (2). In this regard, it would be critical to
eadily identify the subset of patients showing higher
latelet activity at baseline and reduced antiplatelet drug
esponsiveness in whom our therapeutic efforts may merit
ore attention (3). Previous studies have demonstrated that
linical status (acute coronary syndrome), risk factors (dia-
etes mellitus, obesity), as well as specific genetic traits may
ead to different degrees of platelet reactivity and respon-
iveness to antiplatelet agents (4–7). However, a compre-
ensive picture of patients with enhanced baseline platelet
ctivity remains elusive. In addition, the final implications of
hese findings and the fate of these “unprotected” patients
emain to be evaluated in large scale clinical studies.
Second, the loading dose and the time-delay interval
etween clopidogrel administration and PCI proved to be of
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Editorial Comment November 7, 2006:1751–4aramount importance. A 600-mg loading dose is increas-
ngly used in daily clinical practice. This loading dose
egimen is associated with more rapid platelet inhibition
nd improved responsiveness compared with a 300-mg
oading dose (8–9). Notably, a pre-treatment approach
sing a 600-mg loading dose also appears to translate into
etter clinical outcomes without any increase in bleeding
azards (10). Despite such observations, a high clopidogrel
oading dose regimen is still not approved by the U.S. Food
nd Drug Administration, because most clinical efficacy
ata have been accrued with a 300-mg dose. On the other
and, in the present study, patients in whom clopidogrel
as administered relatively close to the procedure had
ncreased platelet aggregation. These findings are in line
ith previous studies and emphasize the importance of
onsidering the phamacokinetic profile of the drug even
hen a 600-mg loading dose is selected (8–9). A post hoc
nalysis of the CREDO (Clopidogrel for Reduction of
vents During Observation) trial showed that a 300-mg
lopidogrel loading dose started to be clinically effective only
fter 12 h of pretreatment (11). In contrast, a retrospective
nalysis of the ISAR-REACT (Intracoronary Stenting and
ntithrombotic Regimen—Rapid Early Action for Coro-
ary Treatment) trial, in which a pre-treatment strategy
sing a 600-mg loading dose regimen in low- to
ntermediate-risk patients was used, failed to detect an
ncremental 30-day clinical benefit from pre-treatment du-
ations 2 to 3 h (12). However, from a pragmatic
erspective, it should be kept in mind that despite the widely
emonstrated benefits of upstream antiplatelet therapy (11),
lopidogrel pre-treatment is still not systematically ensured by
any interventionalists owing to logistic difficulties, perfor-
ance of ad hoc procedures, and the potential fear of required
y-pass surgery.
Last but not least, although the relation between the
xtent of platelet aggregation and the event rate was clear,
nd persisted despite adjusting for potential confounders,
he actual rate of events (in particular, the 1% of myocardial
nfarction) was lower than expected (2). Moreover, the
xternal validity of these findings could be jeopardized by
he high number of patients eventually excluded from the
tudy (one-third of those eligible) owing to thienopyridine
re-treatment (patients at higher risk?). Furthermore, a
etailed classification of events (procedure-related vs. sub-
cute stent thrombosis) would have been of interest owing
o the multifaceted underlying pathophysiology. In this
egard, the lack of correlation between pre-procedural plate-
et function and the incidence of troponin elevations after
CI (2) constitutes another area of uncertainty.
revious clinical studies relating the extent of platelet
nhibition to clinical outcome. In patients undergoing
CI, several studies have assessed the clinical implications
f individual responsiveness to antiplatelet agents. The
OLD (AU-Assessing Ultegra) study demonstrated a sub-
tantial variability in the level of platelet inhibition in
atients treated with intravenous glycoprotein IIb/IIIa an- tagonist therapy, and the degree of platelet inhibition repre-
ented an independent predictor for the risk of MACE (13). A
roader number of investigations have focused on the clinical
mpact of individual responsiveness to oral antiplatelet agents.
n particular, several studies have identified suboptimal respon-
iveness to aspirin as a predictor of ischemic events at follow-up
n patients with different clinical manifestations of atheroscle-
otic disease, and there is currently growing evidence that
uboptimal responsiveness to clopidogrel also may contrib-
te to poor clinical outcomes (14). In patients undergoing
CI, the implications of the degree of platelet inhibition on
yonecrosis have been extensively investigated (15–16).
otably, Chen et al. (17) observed an increase in procedure-
elated myonecrosis in aspirin-resistant patients despite
lopidogrel pre-treatment.
The role of platelet inhibition on stent thrombosis has also
eceived recent attention in retrospective analyses (18–21).
enaweser et al. (20) showed that patients who had
uffered from stent thrombosis had an impaired response to
spirin and that additional treatment with clopidogrel was
nable to overcome differences in platelet aggregation com-
ared with matched controls. The CREST (Clopidogrel
ffect on Platelet REactivity in Patients With Stent
hrombosis) study (21) showed that high post-treatment
latelet reactivity and incomplete P2Y12 receptor inhibition
ere risk factors for subacute stent thrombosis. Finally,
necdotal—but consistent—evidence from multiple clinical
tudies suggests a close relation between discontinuation of
ntiplatelet therapy and late drug-eluting stent thrombosis
22), boosting the empirical prescription of prolonged dual
ntiplatelet therapy in these patients.
uture challenges and expectations. Assessing platelet
unction currently remains a moving target. Efforts should
e made to identify and standardize the criteria for optimal
latelet inhibition in patients undergoing PCI. This should
lso involve technical and methodologic issues so that the
esults of different trials could be adequately compared. In
he present series, late platelet aggregation was assessed on
TA at 5 min, whereas other reports (7,8) have determined
maximal” aggregation yielding higher readouts. Likewise,
he present study evaluated “absolute” values of post-
reatment platelet activity whereas some previous reports
ave focused on “percentage inhibition” of platelet activity
23). Timing of platelet function assessment is also a critical
ssue. Differing from the EXCELSIOR study (2), the
REPARE POST-STENTING (Platelet Reactivity in
atients and Recurrent Events Post-Stenting) study (24), in
hich patients undergoing nonemergent stenting were
reated with a 300- or 600-mg loading dose of clopidogrel
fter intervention, showed that increased platelet reactivity
ssessed by LTA at discharge was associated with ischemic
isk. Ischemic events occurred in 10% of patients at 30 days
nd in 20% at 6 months. Over 90% of patients with events
ad maximal ADP-induced platelet aggregation values
bove 50%. Notably, that study highlighted that, in addition
o platelet reactivity, clot strength (a measure of thrombin-
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November 7, 2006:1751–4 Editorial Commentnduced fibrin) and rapid fibrin formation (a marker of
hrombin activity) were also associated with events. These
ndings explain the occurrence of events despite treatment
ith aspirin and clopidogrel, suggesting the potential need
or more aggressive thrombin inhibition during interven-
ions in selected patients.
Other variables that may lead to different readouts and
erit attention when comparing results between different
tudies using LTA include agonist type and concentration,
se of native or platelet count-adjusted platelet-rich plasma,
nd anticoagulant selection (25). Further, although most
linical studies on clopidogrel rely on standard LTA, there
re many other modalities to assess its effects (26). Briefly,
efining the extent of platelet function in patients treated
ith antiplatelet agents widely varies, and the definitive
nswer as to which laboratory test is the best marker of
linical efficacy will require correlation with clinical out-
omes in large clinical trials. Hopefully, this will also lead
oward unified definitions that will be welcomed by the
cientific community (14).
Measurements of individual responsiveness to antiplatelet
herapy may allow customized dose titration, and identifi-
ation of a threshold effect would help therapeutic targeting.
he results of the EXCELSIOR study represent an impor-
ant contribution to our understanding of the impact of
latelet reactivity on clinical outcomes in patients undergo-
ng relatively low-risk interventions and underscore that the
one size fits them all” concept does not apply for antiplate-
et drug regimens (2). In fact, despite adequate timing of
re-treatment with a 600-mg clopidogrel loading dose,40%
f patients were above the median value of platelet aggregation
nd had increased risk. The ongoing RESISTOR (Research
valuation to Study Individuals Who Show Thromboxane or
2Y12 Receptor Resistance) trial will use in low-risk patients
ndergoing PCI a point-of-care assay to identify responders or
onresponders to antiplatelet therapy and then randomize
hem to glycoprotein IIb/IIIa inhibitors or placebo to deter-
ine the impact on myonecrosis. Further studies are still
equired in high-risk patients to confirm that measuring
latelet activity provides important and independent prog-
ostic clues. Recent data from the ISAR-REACT II study
27) support the incremental value of upstream glycoprotein
Ib/IIIa inhibitors in high-risk patients pre-treated with a
00-mg clopidogrel loading dose. What else can we do?
ntensification of therapy with an even higher loading dose
f clopidogrel (900 mg) failed to achieve significant reduc-
ions in platelet reactivity compared with 600 mg (28).
herefore, the answer may be in the use of more potent
2Y12 antagonists (AZD6140, prasugrel, cangrelor), char-
cterized by less response variability, currently being evalu-
ted in phase III clinical trials or antagonists of other
latelet targets, such as thrombin-inhibiting drugs (29).
The next challenge will be to identify the best marker of
linical efficacy following standardized therapeutic ap-
roaches and to select patients most likely to benefit from
edious and relatively sophisticated ex vivo functional stud-
1es. Reliable user-friendly point-of-care tests may evolve in
he near future to allow their routine implementation in the
linical setting. Eventually, prospective large-scale studies
hould determine if direct guidance of tailored antiplatelet
herapy—as the result of platelet function testing—might
ranslate into improved clinical outcomes after coronary
nterventions. Only then will we be able to exchange hype for
ope.
eprint requests and correspondence: Dr. Fernando Alfonso,
ardiología Intervencionista, Instituto Cardiovascular, Hospital
niversitario Clínico “San Carlos,” Plaza de Cristo Rey, Madrid
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